Yearly zoledronic acid in postmenopausal osteoporosis.

Yearly zoledronic acid in postmenopausal osteoporosis.

Bibliografski detalji
Glavni autori:	Poole, K, Kaptoge, S, Reeve, J
Format:	Journal article
Jezik:	English
Izdano:	2007

Slični predmeti

EFFECT OF ZOLEDRONIC AND IBANDRONIC ACIDS ON BONE METABOLISM IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
od: O V Yakushevskaya, i dr.
Izdano: (2012-08-01)

Treatment of postmenopausal osteoporosis, patient perspectives &ndash; focus on once yearly zoledronic acid
od: Raj Carmona, i dr.
Izdano: (2009-07-01)

IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis
od: Lin H, i dr.
Izdano: (2021-07-01)

Risk factors analysis in postmenopausal osteoporosis fragility fracture patients after treated with zoledronic acid
od: Ding Yue, i dr.
Izdano: (2017-09-01)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
od: Fernanda Martins Gazoni, i dr.
Izdano: (2023-05-01)

Zoledronic acid does not slow spinal radiographic progression of osteoarthritis in postmenopausal women with osteoporosis and radiographic osteoarthritis
od: L.V. Host, i dr.
Izdano: (2022-03-01)

Evaluating the Clinical Efficacy of Zoledronic Acid in the Prevention and Treatment of Osteoporosis in Postmenopausal Women, Compared with Conventional Medications
od: Fatemeh Rostami-Golmohammadi, i dr.
Izdano: (2015-02-01)

Role of zoledronic acid in the prevention and treatment of osteoporosis
od: Räkel A, i dr.
Izdano: (2011-03-01)

Zoledronic acid infusion for prevention and treatment of osteoporosis
od: John A Sunyecz
Izdano: (2010-10-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
od: Nataliya Vladimirovna Toroptsova, i dr.
Izdano: (2011-06-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
od: Nataliya Vladimirovna Toroptsova, i dr.
Izdano: (2011-06-01)

The Combination Therapy with Zoledronic Acid and Propranolol Improves the Trabecular Microarchitecture and Mechanical Property in an Rat Model of Postmenopausal Osteoporosis
od: Deepak Kumar Khajuria, i dr.
Izdano: (2014-01-01)

The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study
od: Feyzi Gokosmanoglu, i dr.
Izdano: (2016-01-01)

Management of osteoporosis in the aging male: Focus on zoledronic acid
od: Paul K Piper Jr, i dr.
Izdano: (2009-06-01)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
od: Leslie Spangler, i dr.
Izdano: (2023-10-01)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
od: Ruxu You, i dr.
Izdano: (2022-03-01)

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
od: Federica Bellone, i dr.
Izdano: (2021-11-01)

How zoledronic acid improves osteoporosis by acting on osteoclasts
od: Biao Wang, i dr.
Izdano: (2022-08-01)

ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
od: S Yu Vorotnikova, i dr.
Izdano: (2016-12-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
od: N. V. Toroptsova, i dr.
Izdano: (2021-10-01)

Role of zoledronic acid in treatment of osteoporosis and prevention of fractures
od: A. V. Krivova, i dr.
Izdano: (2022-01-01)

Zoledronate prevents bone loss after stroke
od: Poole, K, i dr.
Izdano: (2006)

The effects of zoledronate on iliac bone remodelling in stroke patients
od: Poole, K, i dr.
Izdano: (2007)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
od: Ege Can Serefoglu, i dr.
Izdano: (2010-05-01)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
od: Luca Dalle Carbonare, i dr.
Izdano: (2010-08-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
od: Irina Aleksandrovna Baranova, i dr.
Izdano: (2011-09-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
od: Irina Aleksandrovna Baranova, i dr.
Izdano: (2011-09-01)

Preserving hip bone mineral density following stroke using intravenous zoledronic acid: Findings from a 1 year randomised controlled trial
od: Poole, K, i dr.
Izdano: (2004)

Pathogenesis and treatment of postmenopausal osteoporosis
od: Milhaud, G, i dr.
Izdano: (1983)

Effect of zoledronic acid on muscle metabolism in mice with osteoporosis combined with sarcopenia
od: Weilong Li, i dr.
Izdano: (2024-11-01)

Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial
od: Asif Hussain, i dr.
Izdano: (2023-01-01)

Zoledronic acid: challenges and pitfalls amid rehabilitation in primary osteoporosis and beyond
od: Alexandru Florin Florescu, i dr.
Izdano: (2024-06-01)

Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip
od: Sanjay Agarwala, i dr.
Izdano: (2019-06-01)

Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
od: Jun Xie, i dr.
Izdano: (2019-12-01)

Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis
od: Johann D Ringe
Izdano: (2010-06-01)

Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
od: Rol, i dr.
Izdano: (2009-01-01)

EFFECT OF ZOLEDRONIC ACID THERAPY ON FRACTURE RISK IN THE TREATMENT OF MEN WITH OSTEOPOROSIS
od: Steven Boonen, i dr.
Izdano: (2012-12-01)

Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients
od: Huang CF, i dr.
Izdano: (2021-08-01)

The effects of zoledronate on iliac bone remodelling; a histomorphometric study in stroke patients
od: Poole, K, i dr.
Izdano: (2007)

Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project
od: F. Bertoldo, i dr.
Izdano: (2011-06-01)